Effectiveness of doxifluridine (5′-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens

A 58-year-old man was diagnosed as having type 3 gastric cancer (poorly differentiated adenocarcinoma). He underwent total gastrectomy with splenectomy, as well as D3 dissection, and received postoperative chemotherapy combining oral uracil and futrafur (UFT) with cisplatin (CDDP), but results showed recurrence of multiple abdominal lymph node metastases around the aorta. He therefore received various anticancer drug regimens (irinotecan [CPT-11]/CDDP; 1 M tegafur-0.4 M gimeracil-1 M oteracil potassium [TS-1], methotrexate (MTX)/5-fluorouracil); however, final results showed growth of lymph node metastasis and simultaneous worsening of his general condition. The patient then received combined administration of doxifluridine (5′-DFUR)/docetaxel (5′-DFUR, 1000 mg/body [666.7 mg/m ² ], given by consecutive daily administration, orally, for days 1–14; and docetaxel, 80 mg/body [60 mg/m ² ], on day 8, by venous drip, every 3 weeks). Three courses of this regimen resulted in approximately 90% reduction of the abdominal lymph node size, disappearance of the right cervical lymph node metastasis, reductions of the levels of two tumor markers (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA]19-9), and improvement of his general condition. In total, seven courses of the regimen were carried out. The patient died on day 298 after starting this combined regimen and showed a response period of 126 days. The primary toxicity identified was neutropenia (grade 4), as well as other low-grade (grade 1, 2) hematological and nonhematological toxicities. In the field of gastric cancer treatment, especially for patients showing multiple resistance to anticancer drugs, an effective therapy is critically needed. Received: January 15, 2002 / Accepted: July 8, 2002 Offprint requests to: A. Sato     

Serum biomarker-based validation of a self-administered diet history questionnaire for Japanese subjects

Although several self-administered dietary assessment questionnaires have been developed for Japanese subjects, they have seldom been validated with objective measures. We validated a recently developed self-administered diet history questionnaire (DHQ) with fatty acids in serum phospholipid fractions, alpha- and beta-carotenes and alpha-tocopherol in serum as a gold standard using 86 university workers (42 men and 44 women, age-range=24-67 y). The age-adjusted Pearson partial correlation coefficients between the intakes of marine origin n-3 polyunsaturated fatty acids (PUFA) (crude values, energy-adjusted values by residual method, energy density, and fat density) and the serum phospholipid concentrations (percentage of total fatty acids) were 0.49, 0.51, 0.52, 0.48, and 0.58, 0.69. 0.66, 0.69 in men and women respectively. The correlation coefficients between intakes (microg/d) and the corresponding serum concentrations (micromol/L) were 0.43 and 0.40 in men and 0.42 and 0.60 in women for alpha- and beta-carotene respectively. It was -0.23 in men and -0.22 in women for alpha-tocopherol. The intakes of major foods (g/d) of marine origin n-3 PUFA, alpha- and beta-carotenes showed a relatively high level of correlation with the corresponding serum concentrations, whereas the level was generally lower than those observed in the analysis with the nutrient intakes. The results suggest that DHQ ranks individual adequately for marine origin n-3 PUFA, alpha- and beta-carotene intakes.     

Distinct neuronal subset reveals perikaryal immunostaining for synaptophysin (protein p38) in the striatum of rats

Summary An immunoperoxidase technique was used to locate synaptophysin (protein p38), a major integral membrane glycoprotein of synaptic vesicles, in the rat brain. In addition to a diffuse distribution of nerve terminal stainings for synaptophysin appearing as numerous small puncta, the large-sized cells with spindled or polygonal shapes revealed perikaryal staining for synaptophysin in the striatum. The double labeling with immunofluorescence technique disclosed that the cell bodies, immunoreactive for synaptophysin, appeared to be those of the striatal giant cholinergic neurons. In addition, in rats that underwent the transient middle cerebral artery occlusion, the striatal ischemic lesions with cell type-specific injury revealed a survival of synaptophysin-positive large cells, presumably identical with the cholinergic neurons. The present study suggests that the metabolism and/or axonal transportation of synaptophysin of the giant cholinergic cells may be different from those of other neuronal populations in the striatum. Also, synaptophysin can act as a neurochemical marker for identification of the giant cholinergic neurons in the striatum of rats.Supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan